Stock comparison
ADMA Biologics
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ADMA
ADMA Biologics
Market cap
$1.91B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ADMA | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 48D | 69B | MTD |
| Benjamin Graham | 55D | 65B | MTD |
| Philip Fisher | 59C | 63C | MTD |
| Peter Lynch | 82C | 66B | ADMA |
| Joel Greenblatt | 46D | 68B | MTD |
| Charlie Munger | 58D | 74B | MTD |
| Terry Smith | 51C | 70B | MTD |
Side-by-side metrics
| Metric | ADMA | MTD |
|---|---|---|
| Market cap | $1.91B | $22.29B |
| P/E (TTM) | 12.0x | 25.3x |
| EV/EBIT | 10.5x | 21.6x |
| ROIC (TTM) | 27.81% | 36.09% |
| Gross margin | 61.27% | 57.79% |
| Net margin | 32.43% | 21.4% |
| Revenue CAGR 5y | 58.45% | 2.01% |
| EPS CAGR 5y | - | 6.12% |
| Debt / Equity | 0.5x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ADMA leads on
- Revenue CAGR 5y58.45%vs 2.01%+97%
- P/E (TTM)12.0xvs 25.3x+53%
- EV/EBIT10.5xvs 21.6x+51%
- Net margin32.43%vs 21.4%+34%
MTD leads on
- Debt / Equity-vs 0.5x+101%
- Market cap$22.29Bvs $1.91B+91%
- ROIC (TTM)36.09%vs 27.81%+23%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.